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mutations) as a model to study
clearance of beta-amyloid plaques
Christian Humpel *
Laboratory of Psychiatry and Experimental Alzheimer’s Research, Department of Psychiatry and Psychotherapy, Medical
University of Innsbruck, Innsbruck, Austria
Alzheimer’s disease is a severe neurodegenerative disorder of the brain, pathologically
characterized by extracellular beta-amyloid plaques, intraneuronal Tau inclusions,
inflammation, reactive glial cells, vascular pathology and neuronal cell death. The
degradation and clearance of beta-amyloid plaques is an interesting therapeutic
approach, and the proteases neprilysin (NEP), insulysin and matrix metalloproteinases
(MMP) are of particular interest. The aim of this project was to establish and characterize
a simple in vitro model to study the degrading effects of these proteases. Organoytpic
brain vibrosections (120µm thick) were sectioned from adult (9 month old) wildtype
and transgenic mice (expressing amyloid precursor protein (APP) harboring the Swedish
K670N/M671L, Dutch E693Q, and Iowa D694N mutations; APP_SDI) and cultured for 2
weeks. Plaques were stained by immunohistochemistry for beta-amyloid and Thioflavin
S. Our data show that plaques were evident in 2 week old cultures from 9 month
old transgenic mice. These plaques were surrounded by reactive GFAP+ astroglia and
Iba1+ microglia. Incubation of fresh slices for 2 weeks with 1–0.1–0.01µg/ml of NEP,
insulysin, MMP-2, or MMP-9 showed that NEP, insulysin, andMMP-9markedly degraded
beta-amyloid plaques but only at the highest concentration. Our data provide for the first
time a potent and powerful living brain vibrosection model containing a high number
of plaques, which allows to rapidly and simply study the degradation and clearance of
beta-amyloid plaques in vitro.
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Introduction
Sporadic Alzheimer’s disease (AD) is a progressive chronic neurodegenerative disorder (at least
97% of all cases are non-genetic) and is characterized by severe beta-amyloid (Aβ) deposition in
brain (plaques) and in vessels (cerebral Aβ angiopathy, CAA), Tau pathology, cell death of cholin-
ergic neurons, microglial activation, inflammation and cerebrovascular damage. The causes of AD
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are yet unknown, but so far the Aβ cascade (Selkoe, 2002) is the
most prominent hypothesis and is thought to be the primary
event that triggers the pathological cascade in AD. However,
there is still an ongoing controversy if Aβ plaques directly cause
the disease, or if Aβ plaques are generated secondary to another
(e.g., vascular) pathological event.
The amyloid precursor protein (APP) is cleaved by secretases
into Aβ peptides (40, 42, or 43 amino acids), and these pep-
tides aggregate under certain conditions and are deposited as Aβ
plaques. The plaques consist of a central core of highly aggre-
gated Aβ peptides and a halo around the plaques (Wisniewski
et al., 1989). It is well established that the “halo” consists of
degenerating nerve fibers and several infiltrating cells, like reac-
tive astrocytes or microglia. The most robust deficits occur in this
halo around the plaques within a radius of approximately 20µm,
including local alterations in spine density, neuritic curvature,
calcium dysregulation and oxidative stress (Xie et al., 2013). The
“core” consists of a dense aggregation of large or several small
Aβ depositions, especially the toxic Aβ1–42. Brain capillary ves-
sels penetrate the core and it seems that every plaque is associated
with a vessel.
In severe AD, the whole brain is filled with several Aβ plaques.
Therapeutic options aim to prevent the deposition of plaques
(beta-sheet breaker, secretase inhibitors, Aβ-degrading enzymes)
to degrade and clear the plaques (Glabe, 2000; Wang et al.,
2006). Immune cells, especially microglia are of special inter-
est, because they (or transformed macrophages) may phago-
cyte plaques. However, in AD the phagocytic activity of these
microglial cells is diminished (D’Andrea et al., 2004; Lee and
Landreth, 2010). Thus, strategies explore if endogenous blood
cells, especially monocytes, may enter the brain and migrate to
plaques; indeed in the AD mouse model this has been demon-
strated (Lebson et al., 2010; Hohsfield et al., 2014). Alternatively,
it seems likely that infusion of plaque-degrading enzymes may
be an attractive strategy to destruct plaques. Indeed, several Aβ-
degrading proteases have been identified, including neprilysin
(NEP; Iwata et al., 2001; Leissring et al., 2003; Marr et al., 2003),
insulin-degrading enzyme (IDE; Qiu et al., 1998; Bennett et al.,
2000; Kurochkin, 2001; Farris et al., 2003; Leissring et al., 2003),
endothelin-converting enzyme (ECE; Eckman et al., 2001, 2002),
angiotensin-converting enzyme (ACE;Hu et al., 2001), plasmino-
gen activators (Van Nostrand and Porter, 1999; Ledesma et al.,
2000; Tucker et al., 2000), myelin basic protein (Liao et al.,
2009) or different matrix metalloproteinases, such as e.g., MMP-
2 (gelatinase A/type IV collagenase) (Roher et al., 1994; Yamada
et al., 1995) and MMP-9 (Backstrom et al., 1996; Yin et al., 2006).
However, these proteases have partly a wide range of sub-
strates, are large molecules, and cannot pass the bood-brain bar-
rier (BBB) and find their targets. Different strategies have been
tested, especially in vivo in AD mouse models. However, these
animal models are all very complex, either because the proteases
need to be overexpressed using adeno- or lentiviral vectors (Guan
et al., 2009; Liu et al., 2010) or because the enzymes are intracra-
nially injected directly into the brain (Park et al., 2013; Walker
et al., 2013) or peripherally applied (e.g., i.v.). Further, studies
failed due to the lack of BBB penetration or the short half-life
of the enzymes (Davis et al., 2004; Henderson et al., 2014). Thus
in order to test a time- and dose specificity and selectivity and a
possible combination of these enzymes, we certainly need easy to
use in vitromodels.
The aim of the present study was to develop a simple in vitro
model which contains plaques and can be used to screen for
plaque-degenerating enzymatic activity. So far no in vitro mod-
els exist, which contain plaques. As we have long-time experi-
ence in organotypic brain slices, we aimed to develop an in vitro
organotypic vibrosection model which contains plaques and can
be used to screen for clearance activities. We report here for
the first time, that vibrosections prepared from adult whole
brain Alzheimer mice are useful to screen different Aβ-degrading
enzymes and this method is easy, fast and potent.
Materials and Methods
APP_SDI Mice and Controls
Wildtype (C57BL/6N) and transgenic APP_SDI (expressing
amyloid precursor protein (APP) harboring the Swedish
K670N/M671L, Dutch E693Q, and Iowa D694N mutations;
C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax) mice were
purchased from The Jackson Laboratory and housed at the Medi-
cal University of Innsbruck animal facility providing open access
to food and water under 12/12 h light-dark cycles. The mice
have been generated and extensively characterized by Davis et al.
(2004).
Organotypic Vibrosections of Adult Mice
For vibrosection cultures 9 month old adult mice were used. All
experiments conformed to Austrian guidelines on the ethical use
of animals and all efforts were made to minimize the number
of animals used and their suffering. For all experiments a min-
imum of n = 6 slices was analyzed. Usually 2 slices per group
including a control were incubated, which was repeated at least
in 3 independent experiments. Vibrosections were performed as
described in detail under sterile conditions (Ullrich et al., 2011).
The animals were rapidly sacrificed, the brains dissected and
sagittally cut. The brains were glued (Glue Loctite) onto the chuck
of a water cooled vibratome Leica VT1000A (UV sterilized and
under a Laminar Flow), and triggered close to a commercial
shave racer. Under aseptic conditions, 120µmvibrosections were
cut and collected in sterile medium. The organotypic vibrosec-
tions were carefully placed onto a sterile 0.4µm pore mem-
brane (Millipore HTTP02500), which was then placed into a
0.4µmmembrane insert (Millipore PICM03050) within a 6-well
plate. Vibrosections were cultured in 6-well plates (Greiner) at
37◦C and 5% CO2 with 1.2ml/well of the following culture
medium: 50%MEM/HEPES (Gibco), 25% heat inactivated horse
serum (Gibco/Lifetech, Austria), 25% Hanks’ solution (Gibco),
2mM NaHCO3 (Merck, Austria), 6.5mg/ml glucose (Merck,
Germany), 2mM glutamine (Merck, Germany), pH 7.2. Vibro-
sections were incubated for 2 weeks where they attach to the
membranes. In order to study if slices develop plaques, vibro-
sections from 4 month old APP_SDI Tg mice (which display no
plaques at this stage) were incubated for up to 5 months.
Recombinant proteases were dissolved in 100µl sterile
medium, aliquoted and stored frozen at −20◦C; at the day
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of use, aliquots were diluted in sterile medium and not fil-
tered. Vibrosections were cultured with or without 1, 0.1, or
0.01µg/ml recombinant human neprilysin/CD10 (R&D, Nr.
1182-ZNC-010), human insulysin/IDE (R&D systems, nr. 2496-
ZN-010), human matrix-metalloproteinase-2 (MMP-2; Pepro-
tech Nr. 420-02) or human matrix-metalloproteinase-9 (Sigma,
nr. M8945). At the end of the experiment, vibrosections were
fixed for 3 h at 4◦C in 4% paraformaldehyde (PAF)/10mM
phosphate-buffered saline (PBS) and then stored at 4◦C in PBS
until use.
Immunohistochemistry
Immunohistochemistry was performed as previously described
under free-floating conditions (Ullrich et al., 2011). The vibrosec-
tions were washed with PBS and incubated in PBS/0.1% Triton
(T-PBS) for 30min at 20◦C while shaking. To quench endoge-
nous peroxidase, sections were treated with PBS/1%H2O2/5%
methanol. After incubation, the sections were then blocked
in T-PBS/20% horse serum (GIBCO Invitrogen)/0.2% BSA
(SERVA) for 30min at 20◦C shaking. Following blocking with
mouse IgG blocking reagent (Vector MKB-2213), brain sec-
tions were incubated with primary antibody [beta-amyloid, 1–
16 (6E10) Covance SIG-39300; glial fibriallary acid protein
GFAPMillipore AB5541; microglial Iba1 Wako 019-19741] in T-
PBS/0.2% BSA overnight at 20◦C. The sections were then washed
and incubated with the corresponding biotinylated secondary
(Aβ-mouse; GFAP-chicken; Iba1-rabbit) antibody (1:200, Vec-
tor Laboratories) in T-PBS/0.2% BSA for 1 h at 20◦C shaking.
Following secondary antibody incubation, sections were rinsed
with PBS and incubated in avidin-biotin complex solution (Elite
ABC kit, Vector Laboratories) for 1 h at 20◦C shaking. Finally,
the sections were washed with 50mM Tris-buffered saline (TBS)
and then incubated in 0.5mg/ml 3,3′-diaminobenzidine (DAB,
Sigma)/TBS/0.003% H2O2 at 20
◦C in the dark until a sig-
nal was detected. Once DAB staining was visible, the reac-
tion was stopped by adding TBS to the sections. The brain
sections were rinsed with TBS, inserted into a 6-well plate
(slice down to well surface) directly onto a drop of Vectashield
(Vector), cover-slipped and then evaluated under an inverse
microscope (Leica DM IRB). Some sections were stained with
Thioflavin S (Sigma) to label plaques. Some sections were stained
for fluorescence using Alexa-488 (Aβ) and using Alexa-546
(GFAP).
Western Blot
Western blot analysis was performed as previously described by
us (Hohsfield et al., 2014). Slices were incubated for 2 weeks,
and all slices from 3 wells were taken and pooled in an Eppen-
dorf tube, then dissolved in 100µl ice-cold PBS containing a
protease inhibitor cocktail (P-8340, Sigma), homogenized using
an ultrasonic device (Hielscher Ultrasonic Processor, Germany)
and then centrifuged at 16,000 × g for 60min at 4◦C. The
supernatant was collected (=soluble extract) and the pellet was
dissolved in 50µl 70% formic acid, vortexed and neutralized
with 150µl 7N NaOH (=insoluble extract). Then, 20µl of the
extracts were loaded onto 10% Bis-Tris SDS-polyacrylamide gels,
and separated for 25min at 200V and then electrotransferred to
nylon-PVDF Immobilon-PSQ membranes for 90min at 30V in
20%methanol blotting buffer. TheWestern Breeze Chromogenic
System was used for the detection of specific proteins in corti-
cal extracts. Briefly, blots were blocked for 30min in blocking
buffer, incubated with primary antibodies against beta-amyloid
(1:1000) at 4◦C overnight, washed, and then incubated in alka-
line phosphatase conjugated anti-mouse IgG for 30min. After
washing, bound antibodies were detected using an enhanced
chemiluminescence (ECL) system. As a control aggregated beta-
amyloid standards (Calbiochem Aβ1–42, PP69, Mw = 4417 kDa)
were loaded. Aggregation was performed as described by Ryan
et al. (2010). Briefly, 250µg recombinant Aβ1–42was dissolved in
250µl 5% acidic acid (226µM), 10min sonicated in a water bath,
then diluted to 100µM in PBS + 0.005% sodiumdodecylsulfate
(SDS), then incubated overnight at 4◦C, and further diluted in
PBS to 11µM, and incubated for 2 weeks at 4◦C. Then the aggre-
gates were further incubated for 2 weeks at 37◦C with or without
1µg/ml MMP-9.
Evaluation of Plaques
Vibrosections at the cortical level were photographed with the
Leica inverse microscope at a 10× magnification under a red fil-
ter. The exposure time was always 23ms with the bright light set
at the lowest level. The software Openlab was used at a Mac com-
puter connected to the microscope. Pictures were saved as JPG
files and the analysis was performed using Image J. The pictures
were transformed to a 8-bit grayscale image. The calibration was
set at 0.470 (distance in pixels), 1.00 (known distance), 1.0 (pixel
aspect ratio) andµm (unit in lenght) and global was activated.
The picture was transformed into a binary image and the thresh-
old was adapted to 30–40. The number of particles was counted
setting the size to 100–8000µm2. The number of plaques was
counted in a defined circle in 2.5mm2 area. Examples of plaque
evaluations are given in the Figures 4E–G.
Statistical Analysis
Statistical analysis was performed by a Kruskal–Wallis test and
Dunn’s post-hoc test, where p < 0.05 represents significance.
Results
Plaques in the 9 Month Old APP_SDI Mice
Organotypic vibrosections were cultured for 2 weeks and the
plaques were stained by immunohistochemistry for Aβ or
Thioflavin S. In cultured wildtype mice vibrosections (9 month
old, 120µm, 2 weeks) no plaques were visible (Figure 1A). In
cultured APP_SDI mice vibrosections a high number of plaques
were stained by Aβ immunostaining (Figure 1B) or Thioflavin
S dye (Figure 1D). As a control the primary antibody was
omitted in transgenic vibrosections and no plaques were found
(Figure 1C). It became evident, that reactive astrocytes express-
ing GFAP were markedly enhanced in transgenic (Figure 2B) but
not wildtype (Figure 2A) vibrosections, which centered around
the Aβ plaques (Figures 2E–G). Similarly, microglial Iba1 stain-
ing was markedly increased in transgenic versus wildtype vibro-
sections (Figures 2C,D).
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FIGURE 1 | Beta-amyloid plaques in the amyloid-precursor protein_SDI
mouse model vibrosections. Organotypic vibrosections (120µm thick) of 9
month old wildtype (Wt, A) or transgenic (Tg, B–D) mice were prepared and
cultured for 2 weeks, then fixed and immunohistochemically stained for
beta-amyloid (A–C) or Thioflavin S (D). As a control Tg sections were stained
without primary antibody (C). Note a dense number of plaques in 2 week old
cultured vibrosections of 9 month old APP_SDI mice (B). Scale bar in
A = 200µm (A–C) and 120µm (D).
Development of Plaques
In order to study if slices develop plaques, vibrosections from 4
month old APP_SDI Tg mice (which display no plaques at this
stage) were incubated for up to 5 months and then stained for Aβ
plaques. Slices incubated for 1 or 2 months did not show any Aβ
staining (Figures 3A,B). However, after 3 months and more pro-
nounced after 4 and 5 months of incubation several intracellular
Aβ-like depositions were seen, but no extracellular plaques were
found (Figures 3C–E).
Clearance of Plaques
When 9month old vibrosections of APP_SDImice were cultured
for 2 weeks with 1µg/ml recombinant neprilysin (Figure 4D)
or insulysin or MMP-9, a significant reduction of the num-
ber of plaques was observed (Figure 5) compared to controls
(Figure 4A). The incubation with 1µg/ml MMP-2 was not suc-
cessful (Figure 5). No effect on plaque clearance was seen when
the vibrosections were incubated with 100 or 10 ng/ml of all
tested enzymes (Figures 4B,C, 5).
Western Blot Analysis
The Aβ standards were detectable as a small peptide at approx-
imately 4 kDa with a detection limit as low as 10 ng per
lane (Figure 6). When aggregated Aβ was loaded several aggre-
gated forms (mainly 8–12–16 kDa) were visible, however, also
larger smear-like aggregates were found (Figure 6). No Aβ-
immunoreactivity was seen in soluble aggregates or soluble slice
extracts (Figure 6). When insoluble slice extracts were analyzed
by Western Blot, no staining was seen in Wt mice, however, a
FIGURE 2 | Characterization of plaques in vibrosections of 9 month old
amyloid-precursor protein_SDI transgenic mouse model. Organotypic
vibrosections of 9 month old wildtype (Wt; A,C) or transgenic (Tg; B,D–G) mice
were prepared (120µm thick) and cultured for 2 weeks, then fixed and
immunohistochemically stained for astroglial glial-fibrillary acidic protein (GFAP;
A,B,F) or microglial Iba1 (C,D). Astroglial GFAP (F) was co-stained with
beta-amyloid (E), showing reactive astroglia around plaques (G). Scale bar in
A = 150µm (A–D) and 100µm (E–G).
strong staining was seen for 4–16 kDa Aβ forms and a strong
larger smear (Figure 6). However, no clear difference was seen
between MMP-9 treated or untreated vibrosections (Figure 6).
Discussion
The organotypic brain slice and vibrosection model is well-
established and serves as a validated tool to study neurode-
generation or neuroprotection (Stoppini et al., 1991; Gähwiler
et al., 1997; Schatz et al., 1999; Weis et al., 2001; Humpel and
Weis, 2002; Ullrich et al., 2011). Usually brain slices are derived
from young postnatal brains, however, such slices are not useful,
because plaques develop usually between 4 and 6 months of age
in tg mice. Previously, we have developed a model from postna-
tal wildtype rats (Marksteiner and Humpel, 2008), however, such
“Aβ-like depositions” are not fully comparable to the Aβ plaques-
derived from adult brains. In the present study we developed for
the first time an organotypic vibrosection model from adult AD
mice, and demonstrate that this model shows Aβ plaques and is
useful to screen for Aβ-degrading enzymes.
Adult Brain Slices
Usually most brain slices are derived from postnatal animals, as
it is difficult to properly prepare and maintain adult slices. Cul-
turing of adult brain slices is very tricky and has been reported
by only a few groups with several limitations, especially the short
life time and reduced viability of the slices. Finley et al. (2004)
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FIGURE 3 | Vibrosections from 4month old APP_SDI mice (having no
plaques at this stage) were incubated for 1 (A), 2 (B), or 5 (C–E) months,
then fixed and stained for Aβ. No staining was visible after 1 or 2 months of
incubation, however, after 3 and more pronounced after 4 and 5 months several
Aβ+ intracellular depositions were seen. The 2 pictures in the last row (D,E)
show high magnifications taken from panel (C). However, at any stage no
extracellular plaques were found. Scale bar in A = 200µm (A–C) and
12µm (D,E).
cultured juvenile young adult (postnatal P20-21 days) hippocam-
pal slices and reported maintained neuronal architecture and
synaptic activity. Kim et al. (2013) established adult organotypic
hippocampal slices in serum-free culture medium for 30 days and
found well preserved astrocytes, neural processes and synapses.
Su et al. (2011) cultured adult hippocampal slices which led to
a time-dependent reproducible cell death. They reported that
slices lost 50% of their cells after 6 days in vitro, while brain-
derived neurotrophic factor supplementation promoted cell sur-
vival. Wilhelmi et al. (2002) reported the culturing of adult
hippocampal slices in a cerebrospinal fluid-like medium, which
markedly prolonged culture times up to 5–6 days. Anyhow, the
need of special supplemented adult slice (serum-free) medium
needs to be further optimized. So far, none of the published
conditions for adult slices are accepted and established.
Development of Plaques in Vibrosections
In our first approach we wanted to test if plaques develop in
organotypic vibrosections. Thus, we cultured brain sections from
4 month old transgenic mice. At this stage no plaques are seen
FIGURE 4 | Effects of neprilysin on beta-amyloid (Aβ) plaques in 9
month old amyloid-precursor protein_SDI mouse model vibrosections
and computer-assisted analysis (E-G). Organotypic vibrosections of 9
month old wildtype (Wt, A,E) or transgenic (Tg, B–D,F,G) mice were prepared
(120µm thick) and cultured for 2 weeks without (A,B) or with 10 ng/ml (C) or
1µg/ml (D) neprilysin, then fixed and immunohistochemically stained for
beta-amyloid (A–G). Note the decreased number of plaques in vibrosections
incubated with 1µg/ml recombinant neprilysin for 2 weeks (D). The number of
plaques was counted using computer-assisted imaging (E–G), showing no
plaques in Wt vibrosections (E), a high number of plaques in Tg vibrosections
(F) and a reduced number of plaques in the neprilysin treated vibrosections
(G). Scale bar in A = 200µm (A–G).
in the brain. We hypothesized that culturing of such slices for
up to 5 months may induce Aβ plaque deposition, because 9
month old tg mice contain a large plaque load. Our data shows
that up to 2 months of culturing, no Aβ-immunostaining was
evident, however, after 3–5 months of culturing a strong intra-
cellular Aβ immunoreactivity was found. At any stage we never
observed extracellular Aβ plaque depositions in the vibrosec-
tions. Thus, this model may not be useful to screen for the
effects of Aβ-degrading enzymes, but may rather be very useful
to test the processes of Aβ processing, release and extracellular
deposition to plaques. Thus, further experiments are necessary
to test the conditions and factors, which may induce an extra-
cellular plaque deposition in vitro similar as seen in the vivo
situation.
Plaques in Advanced AD Stages
In order to study plaques in vitro and to investigate Aβ-degrading
enzymes, we developed an in vitro vibrosection model from 9
month old tg mice, which contain a high plaque load at this stage
in the whole brain (Davis et al., 2004). Our data clearly show
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FIGURE 5 | Quantitative analysis of beta-amyloid (Aβ) plaques in the
cortical vibrosections. Vibrosections of 9 month old adult
amyloid-precursor protein_SDI mouse model were cultured for 2 weeks
without (CO) or with 10, 100, or 1000 ng/ml neprilysin, insulysin, matrix
metalloproteinase (MMP) −2 or −9. Slices were then fixed and
immunohistochemically stained for plaques with a beta-amyloid antibody. As
a comparison the number of plaques is given from brain sections at day zero
(d0). The number of beta-amyloid plaques was evaluated using
computer-assisted microscopy. Values are given as mean ± SEM plaques
per 2.5mm2; the values in parenthesis give the number of analyzed slices.
Statistical analysis was performed by a Kruskal–Wallis test and Dunn’s
post-hoc test (∗p < 0.05; ∗∗p < 0.01).
that culturing of 120µm adult vibrosections for 2 weeks main-
tains many Aβ plaques. These plaques in vitro are typically of
the same pattern and size as the plaques seen in vivo, showing
strong Aβ depositions. The number of plaques did not increase
during culturing for 2 weeks. Using Western blots we confirmed
that the vibrosections contained aggregated insoluble Aβ at this
stage. Further we show, that these plaques are surrounded by
reactive healthy GFAP+ astrocytes. Similarly, also reactive Iba1+
microglia have been found in these slices. This is a typical cellular
pattern, that reactive glial cells surround the plaques. However,
we cannot exclude that additional traumatic effects at both sides
of the vibrosection occurs due to slicing, which may influence the
plaque composition.
Degradation and Clearance of Plaques with
Neprilysin
Neprilysin is a 85–110 kDa plasmamembrane glycoprotein of the
neutral zinc metalloendo-peptidase family expressed by neurons
and cerebrovascular smooth muscle cells. Neprilysin seems to be
the most potent Aβ-degrading enzyme (Iwata et al., 2001) and
several studies demonstrated its effect. In fact, several cleavage
sites of NEP within the Aβ sequence have been identified (Grimm
et al., 2013). However, it is worth mentioning that NEP cleaves
monomeric Aβ1–40 more efficiently than Aβ1–42; in vitro NEP
degraded 27% of monomeric Aβ1–42, but cleaved 73% of Aβ1–40
monomers (Grimm et al., 2013). It has been shown that intrac-
erebral infusion of a recombinant soluble neprilysin from insect
cells into AD mice improved memory and reduced Aβ accumu-
lation in the brain (Park et al., 2013). Further an intravenous
infusion of a NEP fusion protein resulted in dose-dependent
clearance of Aβ, but did not affect brain Aβ, however, an intracra-
nial infusion was successful (Walker et al., 2013). Liu et al. (2010)
produced a secreted form of NEP by adeno-associated transduc-
tion and showed that plasma NEP decreased plasma Aβ by 30%
and cleared brain Aβ by 28–55% within 3 months. In contrast,
overexpression of NEP on the surface of leucocytes (by lentivi-
ral induction) and periphal infusion reduced soluble Aβ in brain
by 30% and lowered CAA Aβ by 50–60% (Guan et al., 2009).
In contrast, another group fused NEP to albumin to increase
plasma half-life time and showed that repated i.v. infusion for 4
months in Tg2576 mice (and rats and monkeys) cleared plasma
Aβ but not brain or CSF Aβ (Henderson et al., 2014). Some
studies were conducted also in vitro, however, their conclusions
are limited due to the simplicity of the model. Miners et al.
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FIGURE 6 | Western Blot analysis of brain slice extracts. Beta-amyloid
(10–100–500 ng per lane), or aggregated beta-amyloid (2w 4◦C + 2w 37◦C)
or slice extracts (either soluble or insoluble extracts) were loaded onto gels,
separated for 25min, blotted with 20% methanol and analyzed for
beta-amyloid by enhanced chemiluminescence. Size markers are given on
the left side as kDa. Slices were prepared from 9 month old wildtype (Wt) or
APP_SDI transgenic (Tg) mice and incubated for 2 weeks with or without
1µg/ml MMP-9 (Wt+ or Tg+).
(2011) showed that NEP overexpression in primary human adult
cerebrovascular smooth muscle cells counteracted Aβ-induced
toxicity. In cultured astrocytes, ketamine (an NMDA antagonist)
and MK-801 decreased NEP expression via de-phosphorylation
of p38MAPK, suggesting that these signal pathways are linked to
Aβ degradation (Yamamoto et al., 2013). All in all, the in vivo
data are partly not conclusive, although NEP seems to have
the most prominent Aβ-degrading activity. Our present data
indeed show that recombinant NEP degrades Aβ plaques, but
only at the highest concentration of 1µg/ml. However, we can-
not exclude that the added proteases underwent autodegradation
or that the enzymes added to the medium did not efficiently
diffuse into the slice. In this case it would be helpful to deter-
mine the catalytic activity in slice extracts under optimized
conditions.
Insulysin, MMPs, and Other Enzymes
Yan et al. (2006) reported that MMP-9 was very potent to degrade
soluble fibrillar Aβ, but this ability was not shared by other
enzymes examined, including ECE, IDE and neprilysin. In fact,
MMP-9 was also the most potent enzyme to degrade Aβ in
our hands. MMP-9 is a zinc dependent metalloprotease and ini-
tially synthesized as the inactive proenzyme pro-MMP-9, which
is cleaved into an active form upon release by other proteases.
MMP-9 is expressed inmany cells in the brain, neurons, astroglia,
microglia, vascular cells and is increased in the brain of AD
patients (Dzwonek et al., 2004; Nalivaeva et al., 2008). MMP-9
is expressed by reactive astrocytes around Aβ plaques, and it is
suggested that these cells may contribute in plaque clearance (Yan
et al., 2006; Yin et al., 2006).
Our data show, however, in contrast to Yan et al. (2006) that
also neprilysin and IDE was very potent to degrade Aβ plaques.
This must not be necessarily a contrast, because, the cleavage site
of the enzymes must be considered. Studies examining different
fragments of Aβ report on the importance of 2 critical regions for
aggregation at positions 17–21 and 30–35 (see Yan et al., 2006).
The suggested cleavage site of MMP-9 is Phe20-Ala21 and Ala30-
Ile31 (Yan et al., 2006). However, the plaques in the different AD
mouse models are heterogenous, because the mutation sites dif-
fer within the Aβ sequence. In our APP_SDI mouse model 3
mutations have been inserted (Swedish K670N/M671L); Dutch
E22Q (E693Q) and Iowa D23N (D694N). Thus, the effects of the
different proteases can vary in the different AD mouse models
used.
In addition, a number of enzymes or chemicals have been
reported to degrade plaques, however, often their effects are not
well characterized, regarding either dosage or specificity of the
substrate or selectivity to find the targets. Such a new enzyme
is e.g., nardilysin (a N-arginine dibasic convertase; NRDc, ini-
tially identified as a metalloendopeptidase of the M16 family),
which has been reported to prevent amyloid plaque formation by
enhancing alpha-secretase in an AD mouse model (Ohno et al.,
2014). Finally, several other enzymes or substrates may induce
Aβ degradation/clearance in the brain and may become a potent
therapeutic target, such as e.g., BACE2, nattokinase or neprilysin-
2 (Nalivaeva et al., 2008; Hsu et al., 2009; Hafez et al., 2010;
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Abdul-Hay et al., 2012). Further, different substrates (e.g., estro-
gens or BRI2 protein) may indirectly have Aβ-degrading activity
via activation of Aβ-degrading enzymes (Kilger et al., 2011;Merlo
and Sortino, 2012).
Advantage of the Adult AD In Vitro Model
Many of the reported enzymes have been shown to degrade sol-
uble Aβ, but not all of them have been convincingly shown to
degrade Aβ fibrils or compact plaques. The problems and limits
are clearly that the effects of these enzymes cannot be easily stud-
ied in vivo in mouse models. The enzymes are large molecules,
do not enter the BBB, have a wide range of substrates and side
effects on peripheral organs or blood cells, when administered
into the vein. Intraventricular infusions break up the BBB result-
ing in influx of blood-derived substrates and enzymes. Further,
the stability of the applied enzymes is a problem, and only small
amounts may enter the plaque site. An interesting experimental
approach has been reported by Yan et al. (2006), who prepared
5µm thin snap frozen cryostat sections from saline perfused
AD mice (APP/PS1), incubated them in 70 nM protease (MMP-
9, ECE, IDE, NEP) at 37◦C for 5 days and stained them with
Thioflavin S and observed degradation of plaques by MMP-9
only. This is an interesting model, however, since the slices have
been fresh frozen, they are no longer considered as “living.” So
far good in vitro models are missing and our novel model may
provide for the first time a compact system to demonstrate clear-
ance of plaques directly in a living mouse brain model allowing
to study time- and dose-dependent effects.
Limit of the Model
This in vitro AD model has definitively several limitations. The
most severe limitation is the low neuronal viability of the adult
slices. Although it was out of focus to characterize the neu-
ronal viability, we have preliminary data that the very sensi-
tive dopaminergic and cholinergic neurons did not survive well
in our adult wt or tg vibrosections even when incubated with
growth factors. In fact, more work is needed to study and enhance
the survival of neurons in adult slices, and the culture condi-
tions must be adapted and optimized. Further, we cannot exclude
that the enzymes (at highest concentration) may damage the
vibrosections, especially the neurons. Cell death assays includ-
ing e.g., propidiumiodine stainings, neuN immunostainings, and
MAP-2 Western Blots may help to further characterize the adult
slice model. So, far this present model may be limited but very
powerful to study plaque development and degradation using
Aβ-degrading enzymes.
Another problem, although not limited to the slice culture
conditions, is the lack of Tau pathology, the second important
pathological condition in AD. In most APP overexpressing mod-
els only Aβ plaques occur and no Tau pathology is evident.
Alternatively, a triple transgenic mouse model (3xTg-AD, B6;
129-Psen1tm1MpmTg(APPSwe, tauB301L)1Lfa/J) could be useful
which contains βA as well as Tau pathology. The problem is
that the plaques and Tau pathology occur only at very lates age,
approximately at 15–20 months, and it is not very convenient
to use such old mice for cultures. Last not least the transgenic
AD mouse model reflects more a genetic model of AD, which
accounts for only<5% of all AD cases. Asmore than 95% are spo-
radic AD and the causes for AD are not known, animal models
for sporadic AD have not been described to date.
Clear or Prevent?
The application of Aβ-degrading enzymes is a very interesting
therapeutic option to degrade and clear plaques in severe AD
patients. The problems of delivery, stability and selectivity must
be resolved and thus this approach could become a potent tech-
nology to clear plaques at an end-stage. However, we also need
therapeutic options to prevent plaques. Thus strategies need to
be developed to apply such Aβ-degrading enzymes at a very early
stage of the disease, such as in mild cognitive impairment. In fact,
PET analysis shows that some individuals display already plaques
at early age without having any cognitive symptoms. Such thera-
peutic approaches with proteases, however, must be safe, easy and
specific. Organotypic vibrosections may help to understand and
establish such therapeutic options with Aβ-degrading enzymes.
In conclusion our data provide for the first time a potent and
powerful living brain vibrosection model containing a high num-
ber of plaques, which allows to rapidly and simply study the
degradation and clearance of Aβ plaques in vitro.
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